Vanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Vanguard Group Inc. boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,684,561 shares of the biotechnology company’s stock after acquiring an additional 107,635 shares during the period. Vanguard Group Inc. owned 6.22% of Arcturus Therapeutics worth $28,587,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ARCT. Franklin Resources Inc. grew its stake in shares of Arcturus Therapeutics by 54.6% in the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after buying an additional 36,714 shares during the last quarter. Empire Life Investments Inc. boosted its stake in Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after purchasing an additional 128,771 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock valued at $1,393,000 after purchasing an additional 47,824 shares during the last quarter. Spire Wealth Management raised its holdings in Arcturus Therapeutics by 393.3% in the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Wall Street Analysts Forecast Growth

ARCT has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Canaccord Genuity Group cut their price objective on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Stock Up 4.9 %

ARCT opened at $10.18 on Tuesday. The firm has a 50-day simple moving average of $13.73 and a two-hundred day simple moving average of $16.78. Arcturus Therapeutics Holdings Inc. has a 52 week low of $8.04 and a 52 week high of $45.00. The company has a market capitalization of $276.08 million, a PE ratio of -4.59 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to the consensus estimate of $44.64 million. As a group, sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.